Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Reborn interim report
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Comment by SamV21on Dec 30, 2021 11:01am
85 Views
Post# 34270809

RE:Reborn interim report

RE:Reborn interim report What ? Another useless interim report coming to put on the fridge and dream about .Phase 2 means nothing, 70 % companies make it to Phase 2 worth nothing thus the price of .12 cents, big Pharma doesn't care till end of Phase 3 and that will be years away, unfortunatly Tetra will run out of funds by then.Guy told us Tetra would be marketing Reduvo in the second half of 2021, don't hold your breath on anything he says or stay by your phone waiting for his news all summer .How are those .12 warrants you loaded up on working out for you ?The guy can't even find the light switch in his home office to do a presentation to the world,he will have to go into hiding if Tetra fails or move back to Australia,people have lost too much money on his empty promises and mismanagement. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities